Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

On Tuesday, TransDigm Group's Chief Financial Officer, Michael Lisman, made a $502,515 buy of TDG, purchasing 850 shares at a cost of $591.19 a piece. Bargain hunters can pick up TDG at a price even lower than Lisman did, with the stock trading as low as $581.03 at last check today -- that's 1.7% below Lisman's purchase price. TransDigm Group is trading up about 0.3% on the day Thursday. This purchase marks the first one filed by Lisman in the past year.

And at 9 Meters Biopharma, there was insider buying on Tuesday, by Director Mark A. Sirgo who purchased 73,529 shares for a cost of $1.36 each, for a total investment of $99,999. Before this latest buy, Sirgo bought NMTR at 2 other times during the past twelve months, for a total investment of $123,864 at an average of $0.71 per share. 9 Meters Biopharma is trading trading flat on the day Thursday. Investors have the opportunity to buy NMTR even cheaper than Sirgo did, with the stock trading as low as $1.31 in trading on Thursday -- that's 3.7% below Sirgo's purchase price.

For MarketNewsVideo.com, I'm Sayoko Murase.